Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II two-stage randomized double-blind placebo-controlled study of XKH001 injection in moderate to severe chronic obstructive pulmonary disease
CTR20260806Phase 2Active
- Sponsor
- Zhejiang Xinkanghe Biopharmaceutical Technology
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xkh001 in chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Zhejiang Xinkanghe Biopharmaceutical Technology. Primary endpoints: Safety and tolerability through week 36, Change from baseline in post-bronchodilator FEV1 at week 28 and 2 more. Started Jun 2026; status: active.
02
Drugs
xkh001
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20260806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260806.